- Immunome Inc's IMNM three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against SARS-CoV-2 Lambda (C.37) and Delta AY.1/2 (Delta Plus) variants in preclinical testing.
- Related Content: Immunome's COVID-19 Antibody Shows Neutralizing Activity Against Delta Variant.
- IMM-BCP-01 consists of three antibodies that bind to non-overlapping regions of the spike protein and show combinatorial activity against multiple strains of SARS-CoV-2.
- The project was funded by the U.S. Department of Defense (DOD) in collaboration with the Defense Health Agency (DHA).
- Price Action: IMNM shares are up 7.22% at $16.19 during the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPreclinical Phase
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
